Impact of Familial Ovarian Cancer Registry on Research 1981–2017: Roswell Park Experience
Tóm tắt
Each year in the USA, 22,280 women are diagnosed with ovarian cancer and 14,240 women die each year from this disease. While accounting for only 2.4% of all cancer deaths, the 5-year survival rate is extremely low at 46% which highlights the great need for continued research. The Familial Ovarian Cancer Registry’s goal since its inception has been to provide the tools needed for the development of improved screening, diagnosis and treatment of ovarian cancer. All major articles produced from the inception of the registry using data either from registry pedigrees or registry samples were collected and reviewed by the authors. Articles from the registry have contributed to the field of ovarian cancer research from 1981 to 2017 in many ways from better defining risks associated with ovarian cancer syndromes to looking at specifics of gene mutations in ovarian cancer registry families. The database continues to grow and provide new information for gene sequencing not only from participants but directly from tumor samples collected at Roswell Park Cancer Institute.
Tài liệu tham khảo
American Cancer Society. Cancer facts and figures 2016. Atlanta: American Cancer Society; 2016.
Piver MS, Goldberg JM, Tsukada Y, Mettlin CJ, Jishi MF, Natarajan N. Characteristics of familial ovarian cancer: a report of the first 1,000 families in the Gilda Radner familial ovarian cancer registry. Eur J Gynaecol Oncol. 1996;17(3):169–76.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality—All COD, Aggregated With State, Total U.S. (1969–2014) < Katrina/Rita Population Adjustment > , National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released December 2016. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).
Jishi MF, Itnyre JH, Oakley-Girvan IA, Steven Piver M, Whittemore AS. Risks of cancer among members of families in the Gilda Radner familial ovarian cancer registry. Cancer. 1995;76:1416–21.
Goldberg JM, Piver MS, Jishi MF, et al. Age at onset of ovarian cancer in women with a strong family history of ovarian cancer. Gynecol Oncol. 1997;66:3–9.
Tayo BO, DiCioccio RA, Liang Y, Trevisan M, Cooper RS, Lele S, Sucheston L, Piver MS, Odunsi K. Complex segregation analysis of pedigrees from the Gilda Radner familial ovarian cancer registry reveals evidence for mendelian dominant inheritance. PLoS ONE. 2009;4(6):35939.
Eng KH, Szender JB, Etter JL, Kaur J, Poblete S, et al. Paternal lineage early onset hereditary ovarian cancers: a familial ovarian cancer registry study. PLOS Genet. 2018;12(2):e1007194.
Brightwell RM, Grzankowski KS, Kaur J, Poblete S, Miller A, Lele S, Sucheston-Campbell L, Moysich K, Odunsi KO. Higher than expected frequencies of non-ovarian cancers within a large familial ovarian cancer registry. Am J Clin Clinical Obstet Gynecol. 2015;2(1):39–44.
Smith SA, DiCioccio RA, Struewing J, et al. Localization of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of < 1 cm. Genes Chromosom Cancer. 1994;10:71–6.
Steichen-Gersdorf E, Gallion HH, Ford D, Girodet C, Easton DF, DiCioccio RA, et al. Familial Site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet. 1994;55:870–5.
Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, Jacobs I, Chenevix-Trench G, Ponder BAJ, Gayther SA. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Can Res. 1996;56:3622–5.
Tworek H, Peng R, Fetzer S, Werness BA, Piver MS, Allen HJ, DiCioccio RA. Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors. Cancer Genet Cytogenet. 1999;112:105–18.
Werness BA, Ramus SJ, DiCioccio RA, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, Tsukada Y, Ponder BAJ, Piver MS. Histopathology, FIGO stage and BRCA mutation status of ovarian cancers from the Gilda Radner familial ovarian cancer registry. Int J Gynecol Pathol. 2004;23:29–34.
DiCioccio RA, Piver MS. A Polymorphism in Intron 2 of the TP53 Gene. Clin Genet. 1996;50:108–9.
Werness B, Jobe JS, DiCioccio RA, Piver MS. Expression of p53 induced-tumor suppressor WAF-1 in malignant epithelial ovarian tumors: correlation with p53 and Ki57 immunohistochemistry. Int. J. Gyn. Pathol. 1997;16:149–55.
Werness B, DiCioccio RA, Piver MS. Identical unique p53 mutations in a primary ovarian contralateral ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggests a common clonal origin. Human Pathol. 1997;28:626–30.
DiCioccio RA, Werness BA, Peng R, Allen HJ, Piver MS. Correlation of TP53 Mutatio and p53 expression in ovarian tumors. Cancer Genet Cytogenet. 1998;105:93–102.
Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, et al. Contribution of germline mutations in the RAD51B, RAD51C and RAD51D genes to ovarian cancer in the population. J Clin Oncol. 2015;33(26):2901.
Ramus SJ, S. H.-M., AOCS Study Group., C. M.-L.-C., & Ovarian Cancer Association Consortium., O. K. (n.d.). “Germline Mutations In The BRIP1, BARD1, PALB2 And NBN Genes In Women With Ovarian Cancer“.J Natl Cancer Inst. 2015; 107(11)
Susan J. Ramus, E. D.-C. (n.d.). “Candidate Ovarian Cancer Susceptibility Genes Identified From Whole Exome Sequencing Of Two Affected Individuals Per Family From 28 Ovarian Cancer Families.”. Curr Oncol. 2016; 23(3): e289–e290